Clinical significance of antiphospholipid antibodies in Behcet disease with thrombosis

  • Yukai LI ,
  • Hongyan WANG ,
  • Liang LUO ,
  • Yun LI ,
  • Chun LI
Expand
  • 1. Department of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China
    2. Department of Traditional Chinese Medicine, the People' s Hospital of Yubei District of Chongqing, Chongqing 401120, China
LI Chun, e-mail, 13811190098@163.com

Received date: 2024-07-31

  Online published: 2024-12-18

Supported by

the Beijing Natural Science Foundation(7192211)

Copyright

, 2024, All rights reserved, without authorization

Abstract

Objective: To investigate the distribution and clinical significance of antiphospholipid antibody (aPL) in patients with Behcet disease (BD). Methods: A total of 222 BD patients admitted to the Department of Rheumatology and Immunology in Peking University People' s Hospital from February 2008 to July 2024 were selected retrospectively. General data of the patients including age and gender were collec-ted. Clinical manifestations (including oral ulcers, genital ulcers, and thrombosis) and laboratory indexes (including aPL, human leukocyte antigen-B51, and anti-endothelial cell antibody) were collec-ted. The recurrence of thrombosis in the BD patients with thrombosis was followed up. Chi-square test was used to compare the clinical symptoms and laboratory indicators between aPL positive group and aPL negative group. Log-rank test was used to compare the recurrence rates of the aPL positive group and the aPL negative group, and P correction was performed by Two-stage method. Finally, Graphpad prism was used for plotting. Results: The prevalence of single aPL, double aPL and triple aPL positivity in the BD patients were 22.1%, 0.5% and 1.4%, respectively. The positive rates of anti-cardiolipin antibody, anti-β2 glycoprotein Ⅰ antibody and lupus anticoagulant (LAC) were 10.4%, 1.8% and 13.1%, respectively. The incidence of thrombosis in the aPL positive group was significantly higher than that in the aPL negative group (44.9% vs. 16.9%, P < 0.001). The erythrocyte sedimentation rate [(20.78±4.91) mm/h vs. (15.85±4.29) mm/h, P=0.005], C-reactive protein [(12.97±5.17) mg/L vs. (7.49± 4.22) mg/L, P=0.010] and IgM [(1.55±0.95) g/L vs. (1.12±0.72) g/L, P < 0.001] in the aPL positive group were significantly higher than those in the aPL negative group. LAC positivity was an independent risk factor for thrombosis in the BD patients (OR=8.51, 95%CI: 2.71-26.72, P < 0.001). The recurrence rate of the aPL positive group was higher than that of the aPL negative group, but there was no statistical difference (69.23% vs. 52.17%, P=0.932). Conclusion: Positive LAC and aneurysm are independent risk factors for thrombosis in BD patients. At the same time, positive antiphospholipid antibody can also significantly increase the risk of thrombosis in BD patients, which has important significance for guiding the treatment of BD.

Cite this article

Yukai LI , Hongyan WANG , Liang LUO , Yun LI , Chun LI . Clinical significance of antiphospholipid antibodies in Behcet disease with thrombosis[J]. Journal of Peking University(Health Sciences), 2024 , 56(6) : 1036 -1040 . DOI: 10.19723/j.issn.1671-167X.2024.06.014

References

1 Bulur I , Onder M . Beh?et disease: New aspects[J]. Clin Dermatol, 2017, 35 (5): 421- 434.
2 Saadoun D , Wechsler B . Beh?et' s disease[J]. Orphanet J Rare Dis, 2012, 7, 20.
3 Shapouri-Moghaddam A , Tavakkol Afshari SJ , Rahimi HR , et al. Para-clinical and immunological evaluation in Buerger' s disease as a suspected autoimmune disease: Case series[J]. Rep Biochem Mol Biol, 2021, 9 (4): 379- 384.
4 El-Ageb EM , Al-Maini MH , Al-Shukaily AK , et al. Clinical features of Beh?et' s disease in patients in the Sultanate of Oman: The significance of antiphospholipid antibodies?[J]. Rheumatol Int, 2002, 21 (5): 176- 181.
5 Espinosa G , Font J , Tàssies D , et al. Vascular involvement in Beh?et' s disease: Relation with thrombophilic factors, coagulation activation, and thrombomodulin[J]. Am J Med, 2002, 112 (1): 37- 43.
6 Calamia KT , Schirmer M , Melikoglu M . Major vessel involvement in Beh?et ' s disease: An update[J]. Curr Opin Rheumatol, 2011, 23 (1): 24- 31.
7 Lie JT . Vascular involvement in Beh?et' s disease: Arterial and venous and vessels of all sizes[J]. J Rheumatol, 1992, 19 (3): 341- 343.
8 Islam MA , Alam SS , Kundu S , et al. Prevalence of antiphospholipid antibodies in Beh?et' s disease: A systematic review and meta-analysis[J]. PLoS One, 2020, 15 (1): e0227836.
9 Le Joncour A , Martos R , Loyau S , et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet' s disease[J]. Ann Rheum Dis, 2019, 78 (9): 1274- 1282.
10 Li C , Zuo Y , Zhang S , et al. Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients[J]. Chin Med J (Engl), 2022, 135 (6): 658- 664.
11 Zhang X , Gong Z , Shen Y , et al. Alkaline ceramidase 1-mediated platelet ceramide catabolism mitigates vascular inflammation and abdominal aortic aneurysm formation[J]. Nat Cardiovasc Res, 2023, 2 (12): 1173- 1189.
12 Güng?rer V , Polat MC , ?elikel E , et al. Factors associated with the development of thrombosis in pediatric Beh?et disease[J]. J Clin Rheumatol, 2023, 29 (4): e19- e24.
13 Hatemi G , Christensen R , Bang D , et al. 2018 update of the EULAR recommendations for the management of Beh?et' s syndrome[J]. Ann Rheum Dis, 2018, 77 (6): 808- 818.
14 Seyahi E . Phenotypes in Beh?et' s syndrome[J]. Intern Emerg Med, 2019, 14 (5): 677- 689.
15 Bettiol A , Prisco D , Emmi G . Beh?et: The syndrome[J]. Rheumatology (Oxford), 2020, 59 (Suppl 3): iii101- iii107.
Outlines

/